Chengdu Easton Biopharmaceuticals(688513.SH): Bumetanide Injection Receives Drug Registration Certificate

Chengdu Easton Biopharmaceuticals (688513.SH) announced that the company has recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration, with the drug name: Bumetanide injection. The main component of Bumetanide injection is bumetanide, which is indicated for: (1) Edematous diseases including congestive heart failure, cirrhosis, kidney diseases (nephritis, renal disease, acute and chronic renal failure for various reasons), especially when the use of other diuretics is ineffective, this type of drug may still be effective. Can be used in combination with other drugs to treat acute pulmonary edema and acute brain edema. (2) Hypertension. In the gradient therapy of hypertension, it is not the first choice for treating primary hypertension, but when thiazide diuretics are ineffective, especially when there is renal insufficiency or hypertensive crisis, this type of drug is particularly suitable. (3) Prevention of acute renal failure: used for various reasons leading to inadequate renal blood flow, such as dehydration, shock, poisoning, anesthesia accidents, and circulatory dysfunction, early application while correcting hypovolemia can reduce the chance of acute renal tubular necrosis. (4) Hyperkalemia and hypercalcemia. (5) Dilutional hyponatremia, especially when blood sodium concentration is less than 120mmol/L. (6) Syndrome of inappropriate antidiuretic hormone secretion (SIADH). (7) Treatment of acute drug poisoning, such as barbiturate poisoning. (8) Cases where furosemide is ineffective may still be effective.